AstraZeneca Expands Pipeline With “Reduced Risk” Phase III Program
Executive Summary
AstraZeneca is entering 2006 with an expanded, lower risk Phase III pipeline that concentrates on familiar therapeutic categories
You may also be interested in...
GSK and Targacept partners in pain
GlaxoSmithKline will gain access to Targacept's two lead candidates for pain: TC-2696, currently in a Phase II post-operative pain study in molar extraction patients, and TC-6499, a preclinical candidate for neuropathic pain, under a deal announced July 27. Partnership includes drugs targeting neuronal nicotinic receptors spanning five therapeutic areas, which also include smoking cessation, obesity, addiction and Parkinson's disease. Deal has a potential value of $1.5 million in addition to an upfront payment of $35 million. Program will be overseen by GSK's Center of Excellence for External Drug Discovery, with Targacept responsible for development of candidates through Phase II proof of concept. AstraZeneca has also partnered with Targacept on an NNR candidate for Alzheimer's, which is in Phase IIb (1"The Pink Sheet," Feb. 6, 2006, p. 19)...
GSK and Targacept partners in pain
GlaxoSmithKline will gain access to Targacept's two lead candidates for pain: TC-2696, currently in a Phase II post-operative pain study in molar extraction patients, and TC-6499, a preclinical candidate for neuropathic pain, under a deal announced July 27. Partnership includes drugs targeting neuronal nicotinic receptors spanning five therapeutic areas, which also include smoking cessation, obesity, addiction and Parkinson's disease. Deal has a potential value of $1.5 million in addition to an upfront payment of $35 million. Program will be overseen by GSK's Center of Excellence for External Drug Discovery, with Targacept responsible for development of candidates through Phase II proof of concept. AstraZeneca has also partnered with Targacept on an NNR candidate for Alzheimer's, which is in Phase IIb (1"The Pink Sheet," Feb. 6, 2006, p. 19)...
J&J Aims For Virology Leadership, But Pipeline Covers Traditional Strengths
Johnson & Johnson is positioning itself to become a major player in the virology market through its recently approved protease inhibitor Prezista and the development of two non-nucleoside reverse transcriptase inhibitors